Teva buys into genomics to bolster its in-house R&D

Israeli pharma giant Teva Pharmaceutical ($TEVA) is investing in Cambridge, MA's Immuneering, taking up a stake in the genomics upstart and tapping its expertise to help guide internal drug development. Teva has acquired a 51% share of its partner, the companies said, at the same time agreeing to collaborate on personalized treatments for CNS ailments. Teva plans to use Immuneering's proprietary analytics platform to hone its R&D in the field, relying on its partner to help it make decisions in early development and match the right patients to their ideal therapies, the company said. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.